Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Activity of gamma interferon in combination with pyrimethamine or clindamycin in treatment of murine toxoplasmosis.

Literature DB >> 2115442

Activity of gamma interferon in combination with pyrimethamine or clindamycin in treatment of murine toxoplasmosis.

Abstract

The activity of recombinant gamma interferon (rIFN-gamma) in combination with either pyrimethamine or clindamycin was examined in a murine model of acute toxoplasmosis. Mice received either pyrimethamine or clindamycin alone or in combination with rIFN-gamma. Significantly increased survival and/or time to death was observed in animals treated with pyrimethamine or clindamycin in combination with rIFN-gamma compared to those that received treatment with any of the agents alone.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 1990 PMID： 2115442 DOI： 10.1007/bf01973746

Source DB: PubMed Journal: Eur J Clin Microbiol Infect Dis ISSN： 0934-9723 Impact factor: 3.267

10 in total

1. Zidovudine antagonizes the action of pyrimethamine in experimental infection with Toxoplasma gondii.

Authors: D M Israelski; C Tom; J S Remington
Journal: Antimicrob Agents Chemother Date: 1989-01 Impact factor: 5.191

2. Treatment of toxoplasmic encephalitis with intravenous clindamycin.

Authors: B R Dannemann; D M Israelski; J S Remington
Journal: Arch Intern Med Date: 1988-11

3. [Zidovudine efficacy and tolerance in 32 patients with cerebral toxoplasmosis in the acquired immunodeficiency syndrome].

Authors: C Leport; M Chakroun; S Matheron; W Rozenbaum; E Dournon; B Regnier
Journal: Presse Med Date: 1988-10-15 Impact factor: 1.228

4. Effect of murine interferon gamma on murine toxoplasmosis.

Authors: R E McCabe; B J Luft; J S Remington
Journal: J Infect Dis Date: 1984-12 Impact factor: 5.226

5. Immunohistological study of the anatomic relationship of toxoplasma antigens to the inflammatory response in the brains of mice chronically infected with Toxoplasma gondii.

Authors: F K Conley; K A Jenkins
Journal: Infect Immun Date: 1981-03 Impact factor: 3.441

6. Effect of clindamycin on acute and chronic toxoplasmosis in mice.

Authors: F G Araujo; J S Remington
Journal: Antimicrob Agents Chemother Date: 1974-06 Impact factor: 5.191

7. In vivo synergism of roxithromycin (RU 965) and interferon against Toxoplasma gondii.

Authors: J M Hofflin; J S Remington
Journal: Antimicrob Agents Chemother Date: 1987-02 Impact factor: 5.191

8. In vitro and in vivo activation of human mononuclear phagocytes by interferon-gamma. Studies with normal and AIDS monocytes.

Authors: H W Murray; D Scavuzzo; J L Jacobs; M H Kaplan; D M Libby; J Schindler; R B Roberts
Journal: J Immunol Date: 1987-04-15 Impact factor: 5.422

9. Clindamycin in a murine model of toxoplasmic encephalitis.

Authors: J M Hofflin; J S Remington
Journal: Antimicrob Agents Chemother Date: 1987-04 Impact factor: 5.191

10. Interferon-gamma: the major mediator of resistance against Toxoplasma gondii.

Authors: Y Suzuki; M A Orellana; R D Schreiber; J S Remington
Journal: Science Date: 1988-04-22 Impact factor: 47.728

10 in total

6 in total

1. Paradoxical effect of clindamycin in experimental, acute toxoplasmosis in cats.

Authors: M G Davidson; M R Lappin; J R Rottman; M B Tompkins; R V English; A T Bruce; J Jayawickrama
Journal: Antimicrob Agents Chemother Date: 1996-06 Impact factor: 5.191

2. Treatment with interleukin 12 in combination with atovaquone or clindamycin significantly increases survival of mice with acute toxoplasmosis.

Authors: F G Araujo; C A Hunter; J S Remington
Journal: Antimicrob Agents Chemother Date: 1997-01 Impact factor: 5.191